Osteoarthritis and comorbidity: features of treatment of patients at the present stage | Ukrainian Medical Journal

In this article we discuss problems of osteoarthritis (OA) that don’t let us treat it efficiently. The most important problems are overdue call to doctor, postponed treatment, patient’s lifestyle and comorbidity. We noted ESCEO 2019 recommendations and their differences from another medical societies. We described management of OA, recommended by ESCEO, in details. In the article the posibility of prescription of chondroprotectors (SYSADOA) as the first level treatment instead of nonsteroidal anti-Inflammatory drugs (NSAIDs) is discussed. We present the role of chondroitin sulfate in OA treatment. NSAIDs, hyaluronic acid, corticosteroids, opioid analgesics, surgical intervention as treatment options are also discussed.

References:

1. Allen K.D., Golightly Y.M. (2015) Epidemiology of osteoarthritis: state of the evidence. Curr. Opin. Rheumatol., 27(3): 276–283.
2. Vina E.R., Kwoh C.K. (2018) Epidemiology of Osteoarthritis: Literature Update. Curr. Opin. Rheumatol., 30(2): 160–167.
3. Bruyere O., Honvoa G., Veronesec N. et al. (2019) An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin. Arthrit. Rheumatism, 49: 337–350.
4. Sharon L., Kolasinski S.L., Neogi T. et al. (2020) 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthrit. Care Res., 72(2): 149–162.
5. OARSI (2016) Osteoarthritis: A Serious Disease, Submitted to the U.S. Food and Drug Administration. Dec. 1.
6. Atlas of Osteoarthritis, ESCEO (2018).
7. Сорока Н.Ф. (2008) Биохимические и патофизиологические основы эффективности хондроитинсульфата при остеоартрозе. Здравоохранение, 9: 65–67.
8. Bruyere O., Cooper C., Pelletier J.-P. et al. (2014) An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin. Arthritis Rheum., 44(3): 253–263.
9. Bruyere O., Cooper C., Pelletier J.-P. et al. (2016) A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis From evidence-based medicine to the real-life setting. Semin. Arthritis Rheum., 45(Suppl. 4S): S3–S11.
10. Messier S.P., Resnik A.E., Beavers D.P. et al. (2018) Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res. (Hoboken), 70(11): 1569–1575.
11. Conaghan P.G., Arden N., Avouac B. et al. (2019) Safety of paracetamol in osteoarthritis: what does the literature say? Drugs Aging, 36 (Suppl. 1): 7–14.
12. Martel-Pelletier J., Farran A., Montell E. et al. (2015) Discrepancies in com-position and biological effects of different formulations of chondroitin sulfate. Molecules, 20(3): 4277–4289.
13. Imada K., Oka H., Kawasaki D. et al. (2010) Anti-arthritic action mechanisms of natural chondroitin sulfate in human articular chondrocytes and synovial fibroblasts. Biol. Pharm. Bull., 33(3): 410–414.
14. Volpi N. (2009) Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J. Pharm. Pharmacol., 61(10): 1271–1280.
15. Rainsford K.D. (2009) Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique. J. Pharm. Pharmacol., 61(10): 1263–1270.
16. Lauder R.M. (2009) Chondroitin sulfate: a complex molecule with potential impacts on a wide range of biological systems. Complement. Ther. Med., 17(1): 56–62.
17. Jordan K.M., Arden N.K., Doherty M. et al. (2003) EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. Dec., 62(12): 1145–1155.
18. Volpi N. (2019) Chondroitin Sulfate Safety and Quality. Molecules, 24(8): 1447.
19. Аникин С.Г., Алексеева Л.И. (2012) Хондроитин сульфат: механизмы действия, эффективность и безопасность при терапии остеоартрита. Соврем. ревматол., 2: 78–82.
20. Reginster J.Y., Dudler J., Blicharski T., Pavelka K. (2017) Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CON-CEPT). Ann. Rheum. Dis., 76(9): 1537–1543.
21. Pelletier J.P., Raynauld J.P., Beaulieu A.D. et al. (2016) Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. Arthritis Res. Ther., 18(1): 256.
22. Schneider H., Maheu E., Cucherat M. (2012) Symptom-Modifying Effect of Chondroitin Sulfate in Knee Osteoarthritis: A Meta-Analysis of Randomized Placebo-Controlled Trials Performed with Structum. Open Rheumatol. J., 6: 183–189.
23. Kloppenburg M., Féline PB Kroon F.P.B. et al. (2018) 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann. Rheum. Dis., 0: 1–9.
24. Zhang W. (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis., 64: 669–681.
25. Eriksen P., Bartels E.M., Altman R.D. et al. (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptom-atic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res. (Hoboken), 66(12): 1844–1855.
26. Pavelka K., Gatterova J., Olejarova M. et al. (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, pla-cebo-controlled, double-blind study. Arch. Intern. Med., 162(18): 2113–2123.
27. Bruyere O., Pavelka K., Rovati L.C. et al. (2008) Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, rand-omised, placebo-controlled trials. Osteoarthritis Cartilage, 16(2): 254–260.
28. Gregori D., Giacovelli G., Minto C. et al. (2018) Associa-tion of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA, 320 (24): 2564–2579.
29. Runhaar J., Rozendaal R.M., Middelkoop M.V. et al. (2017) Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann. Rheum. Dis., 76(11): 1862–1869.
30. Sakellariou G., Conaghan P.G., Zhang W. et al. (2017) EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis. Ann. Rheum. Dis., 76(9): 1484–1494.
31. Yang S., Eaton C.B., McAlindon T.E., Lapane R.L. (2015) Effects of glucosamine and chondroitin on treating knee osteoarthritis: an analysis with marginal structural models. Arthrit. Rheumatol., 67(3): 714–723.
32. Roman-Blas J.A., Castaneda S., Sanchez-Pernaute O. et al. (2017) Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and func-tional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol., 69(1): 77–85.
33. Altman R.D. (2009) Glucosamine therapy for knee osteoarthritis: pharmacokinetic con-siderations. Expert Rev. Clin. Pharmacol., 2(4): 359–371.
34. Jackson C.G., Plaas A.H., Sandy J.D. et al. (2010) The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthrit. Cartilage, 18(Iss. 3): 297–302.
35. Appelboom T., Schuermans J., Verbruggen G. et al. (2001) Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthri-tis. A double blind, prospective, placebo-controlled study. Scand. J. Rheumatol., 30(4): 242–247.
36. Bartels E.M., Bliddal H., Schondorff P.K. et al. (2010) Symp-tomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthrit. Cartilage, 18(3): 289–296.
37. Honvo G., Reginster J-Y., Rabenda V. et al. (2019) Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging., 36(Suppl. 1): 65–99.
38. Pelletier J.P., Martel-Pelletier J. (2018) Diacerein-containing products: same risk of diarrhoea? Aging Clin. Exp. Res., 30(4): 411–412.
39. EMA (2018) European Medicines Agency. Assessment report for diacerein containing medicinal products. EMA/527347/2014. Available from: http://www.ema. europa.eu/docs/en_GB/ document_library/ Referrals_document/Diacerein/ European_Commission_final_decision / WC500173145.pdf [Accessed Apr. 27].
40. da Costa B.R., Reichenbach S., Keller N. et al. (2017) Effective-ness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet, 390(10090): e21–33.
41. Pelletier J-P., Martel-Pelletier J., Rannou F., Cooper C. (2016) Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin. Arthritis Rheum.; 45(Suppl. 4): S22–27.
42. Jung S.Y., Jang E.J., Nam S.W. et al. (2018) Comparative effective-ness of oral pharmacologic interventions for knee osteoarthritis: a network meta-analysis. Mod. Rheumatol., 28(6): 1021–1028.
43. Cooper C., Chapurlat R., Al-Daghri N. et al. (2019) Safety of oral non-selective non-steroidal anti-inflammatory drugs in oste-oarthritis: what does the literature say? Drugs Aging, 36(Suppl. 1): 15–24.
44. Alekseeva L.I., Nasonov E.L. (2013) Osteoarthritis and comorbidities. Medicographia, 35: 152–157.
45. Szeto C-C., Sugano K., Wang J-G. et al. (2020) Non-steroidal Anti-Inflammatory Drug (NSAID) Therapy in Patients With Hypertension, Cardiovascular, Renal or Gastrointestinal Comorbidities: Joint APAGE/APLAR/APSDE/APSH/APSN/PoA Recommendations Gut., 69(4): 617–629.
46. Ungprasert P., Cheungpasitporn W., Crowson C.S., Matteson E.L. (2015) Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur. J. Intern. Med., 26(4): 285–291.
47. Ho K.Y., Gwee K.A., Cheng Y.K. et al. (2018) Nonsteroidal Anti-Inflammatory Drugs in Chronic Pain: Implications of New Data for Clinical Practice. J. Pain Res., 11: 1937–1948.
48. Cooper C., Rannou F., Richette P., Bruyere O. et al. (2017) Use of intraarticular hyaluronic acid in the management of knee osteoarthritis in clini-cal practice. Arthritis Care Res. (Hoboken), 69(9): 1287–1296.
49. Pelletier J-P., Raynauld J.P., Abram F. et al. (2018) Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. Arthritis Res. Ther., 20(1): 40.
50. Stitik T.P., Issac S.M., Modi S. et al. (2017) Effectiveness of 3 weekly injections compared with 5 weekly injections of intra-articular sodium hyaluronate on pain relief of products: a systematic review and meta-analysis. Arch. Phys. Med. Rehabil., 98(5): 1042–1050.
51. van Middelkoop M., Arden N.K., Atchia I. et al. (2016) The OA trial bank: meta-analysis of individual patient data from knee and hip osteo-arthritis trials show that patients with severe pain exhibit greater benefit from intra-articular glucocorticoids. Osteoarthritis Cartilage, 24(7): 1143–1152.
52. Juni P., Hari R., Rutjes A.W. et al. (2015) Intraarticular corticosteroid for knee osteoarthritis. Cochrane Database Syst. Rev., 10: CD005328.
53. Pelletier J.P., Martel-Pelletier J., Rannou F., Cooper C. (2016) Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin. Arthritis Rheum., 45(4 Suppl.): S22–27.
54. Zeng C., Dubreuil M., LaRochelle M.R. et al. (2019) Association of Tramadol With All-Cause Mortality Among Patients With. JAMA, 321(10): 969–982.
55. Wang Z.Y., Shi S.Y., Li S.J. et al. (2015) Efficacy and safety of duloxe-tine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med., 16(7): 1373–1385.
56. Nuesch E., Rutjes A.W., Husni E. et al. (2009) Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev., 4: CD003115.